國家級人體生物資料庫整合平台共同資料模式實作指引(NBCT Common Data Model IG)
0.1.0 - trial-use

Publication Build: This will be filled in by the publication tooling

## : SSF2 白血病-白血病分子生物學檢查的評估代碼系統 - TTL Representation

Active as of 2024-08-01

Raw ttl | Download

    @prefix fhir: <http://hl7.org/fhir/> .
    @prefix owl: <http://www.w3.org/2002/07/owl#> .
    @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
    @prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

    # - resource -------------------------------------------------------------------

     a fhir:CodeSystem ;
      fhir:nodeRole fhir:treeRoot ;
      fhir:id [ fhir:v "ssf-2-leukemia-codesystem"] ; #
      fhir:text [
    fhir:status [ fhir:v "generated" ] ;
    fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem ssf-2-leukemia-codesystem</b></p><a name=\"ssf-2-leukemia-codesystem\"> </a><a name=\"hcssf-2-leukemia-codesystem\"> </a><a name=\"ssf-2-leukemia-codesystem-en-US\"> </a><p>This case-sensitive code system <code>https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">000<a name=\"ssf-2-leukemia-codesystem-000\"> </a></td><td>正常</td></tr><tr><td style=\"white-space:nowrap\">001<a name=\"ssf-2-leukemia-codesystem-001\"> </a></td><td>AML with RUNX1-RUNX1T1</td></tr><tr><td style=\"white-space:nowrap\">002<a name=\"ssf-2-leukemia-codesystem-002\"> </a></td><td>AML with CBFB-MYH11</td></tr><tr><td style=\"white-space:nowrap\">003<a name=\"ssf-2-leukemia-codesystem-003\"> </a></td><td>Acute promyelocytic leukemia with PML-RARA</td></tr><tr><td style=\"white-space:nowrap\">004<a name=\"ssf-2-leukemia-codesystem-004\"> </a></td><td>AML with KMT2A-MLLT3</td></tr><tr><td style=\"white-space:nowrap\">005<a name=\"ssf-2-leukemia-codesystem-005\"> </a></td><td>AML with DEK-NUP214</td></tr><tr><td style=\"white-space:nowrap\">006<a name=\"ssf-2-leukemia-codesystem-006\"> </a></td><td>AML with GATA2, MECOM</td></tr><tr><td style=\"white-space:nowrap\">007<a name=\"ssf-2-leukemia-codesystem-007\"> </a></td><td>AML(megakaryoblastic) with RBM15-MKL1</td></tr><tr><td style=\"white-space:nowrap\">008<a name=\"ssf-2-leukemia-codesystem-008\"> </a></td><td>AML with mutated NPM1</td></tr><tr><td style=\"white-space:nowrap\">009<a name=\"ssf-2-leukemia-codesystem-009\"> </a></td><td>AML with biallelic mutation of CEBPA</td></tr><tr><td style=\"white-space:nowrap\">010<a name=\"ssf-2-leukemia-codesystem-010\"> </a></td><td>AML with mutated FLT3/ITD</td></tr><tr><td style=\"white-space:nowrap\">011<a name=\"ssf-2-leukemia-codesystem-011\"> </a></td><td>AML with mutated FLT3/TKD</td></tr><tr><td style=\"white-space:nowrap\">012<a name=\"ssf-2-leukemia-codesystem-012\"> </a></td><td>AML with MLL-PTD (partial tandem duplication)</td></tr><tr><td style=\"white-space:nowrap\">013<a name=\"ssf-2-leukemia-codesystem-013\"> </a></td><td>AML with BCR-ABL1</td></tr><tr><td style=\"white-space:nowrap\">021<a name=\"ssf-2-leukemia-codesystem-021\"> </a></td><td>B lymphoblastic leukemia/lymphoma with BCR-ABL1</td></tr><tr><td style=\"white-space:nowrap\">022<a name=\"ssf-2-leukemia-codesystem-022\"> </a></td><td>B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged</td></tr><tr><td style=\"white-space:nowrap\">023<a name=\"ssf-2-leukemia-codesystem-023\"> </a></td><td>B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1)</td></tr><tr><td style=\"white-space:nowrap\">024<a name=\"ssf-2-leukemia-codesystem-024\"> </a></td><td>B-lymphoblastic leukemia/lymphoma with IGH/IL3</td></tr><tr><td style=\"white-space:nowrap\">025<a name=\"ssf-2-leukemia-codesystem-025\"> </a></td><td>B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1)</td></tr><tr><td style=\"white-space:nowrap\">041<a name=\"ssf-2-leukemia-codesystem-041\"> </a></td><td>Mixed phenotype acute leukemia with BCR-ABL1</td></tr><tr><td style=\"white-space:nowrap\">042<a name=\"ssf-2-leukemia-codesystem-042\"> </a></td><td>Mixed-phenotype acute leukemia with KMT2A-rearranged</td></tr><tr><td style=\"white-space:nowrap\">051<a name=\"ssf-2-leukemia-codesystem-051\"> </a></td><td>Chronic myelogenous leukemia BCR-ABL1 positive</td></tr><tr><td style=\"white-space:nowrap\">052<a name=\"ssf-2-leukemia-codesystem-052\"> </a></td><td>JAK2 V617F mutation</td></tr><tr><td style=\"white-space:nowrap\">053<a name=\"ssf-2-leukemia-codesystem-053\"> </a></td><td>Myeloid and lymphoid neoplasms with PDGFRA rearrangement</td></tr><tr><td style=\"white-space:nowrap\">054<a name=\"ssf-2-leukemia-codesystem-054\"> </a></td><td>Myeloid and lymphoid neoplasms with PDGFRB rearrangement</td></tr><tr><td style=\"white-space:nowrap\">055<a name=\"ssf-2-leukemia-codesystem-055\"> </a></td><td>Myeloid and lymphoid neoplasms with FGFR1 rearrangement</td></tr><tr><td style=\"white-space:nowrap\">090<a name=\"ssf-2-leukemia-codesystem-090\"> </a></td><td>(1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常</td></tr><tr><td style=\"white-space:nowrap\">091<a name=\"ssf-2-leukemia-codesystem-091\"> </a></td><td>同時有兩種(含)以上上述之分子檢驗異常</td></tr><tr><td style=\"white-space:nowrap\">092<a name=\"ssf-2-leukemia-codesystem-092\"> </a></td><td>同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常</td></tr><tr><td style=\"white-space:nowrap\">8XX<a name=\"ssf-2-leukemia-codesystem-8XX\"> </a></td><td>Molecular study after chemotherapy or immunotherapy or target therapy</td></tr><tr><td style=\"white-space:nowrap\">988<a name=\"ssf-2-leukemia-codesystem-988\"> </a></td><td>不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4)</td></tr><tr><td style=\"white-space:nowrap\">998<a name=\"ssf-2-leukemia-codesystem-998\"> </a></td><td>有執行分子生物學檢查，但結果無法判斷</td></tr><tr><td style=\"white-space:nowrap\">999<a name=\"ssf-2-leukemia-codesystem-999\"> </a></td><td>(1) 病歷未記載或不詳 (2) 未執行分子生物學檢查</td></tr></table></div>"
      ] ; #
      fhir:url [ fhir:v "https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem"^^xsd:anyURI] ; #
      fhir:version [ fhir:v "0.1.0"] ; #
      fhir:name [ fhir:v "SSF2leukemiaCS"] ; #
      fhir:title [ fhir:v "SSF2 白血病-白血病分子生物學檢查的評估代碼系統"] ; #
      fhir:status [ fhir:v "active"] ; #
      fhir:experimental [ fhir:v "false"^^xsd:boolean] ; #
      fhir:date [ fhir:v "2024-08-01T15:33:47+08:00"^^xsd:dateTime] ; #
      fhir:publisher [ fhir:v "國家級人體生物資料庫整合平台"] ; #
      fhir:contact ( [
        ( fhir:telecom [
    fhir:system [ fhir:v "url" ] ;
    fhir:value [ fhir:v "https://ghd.tw/" ]     ] )
      ] ) ; #
      fhir:description [ fhir:v "Assessment of molecular studies in leukemia Code System"] ; #
      fhir:caseSensitive [ fhir:v "true"^^xsd:boolean] ; #
      fhir:content [ fhir:v "complete"] ; #
      fhir:count [ fhir:v "33"^^xsd:nonNegativeInteger] ; #
      fhir:concept ( [
    fhir:code [ fhir:v "000" ] ;
    fhir:display [ fhir:v "正常" ]
      ] [
    fhir:code [ fhir:v "001" ] ;
    fhir:display [ fhir:v "AML with RUNX1-RUNX1T1" ]
      ] [
    fhir:code [ fhir:v "002" ] ;
    fhir:display [ fhir:v "AML with CBFB-MYH11" ]
      ] [
    fhir:code [ fhir:v "003" ] ;
    fhir:display [ fhir:v "Acute promyelocytic leukemia with PML-RARA" ]
      ] [
    fhir:code [ fhir:v "004" ] ;
    fhir:display [ fhir:v "AML with KMT2A-MLLT3" ]
      ] [
    fhir:code [ fhir:v "005" ] ;
    fhir:display [ fhir:v "AML with DEK-NUP214" ]
      ] [
    fhir:code [ fhir:v "006" ] ;
    fhir:display [ fhir:v "AML with GATA2, MECOM" ]
      ] [
    fhir:code [ fhir:v "007" ] ;
    fhir:display [ fhir:v "AML(megakaryoblastic) with RBM15-MKL1" ]
      ] [
    fhir:code [ fhir:v "008" ] ;
    fhir:display [ fhir:v "AML with mutated NPM1" ]
      ] [
    fhir:code [ fhir:v "009" ] ;
    fhir:display [ fhir:v "AML with biallelic mutation of CEBPA" ]
      ] [
    fhir:code [ fhir:v "010" ] ;
    fhir:display [ fhir:v "AML with mutated FLT3/ITD" ]
      ] [
    fhir:code [ fhir:v "011" ] ;
    fhir:display [ fhir:v "AML with mutated FLT3/TKD" ]
      ] [
    fhir:code [ fhir:v "012" ] ;
    fhir:display [ fhir:v "AML with MLL-PTD (partial tandem duplication)" ]
      ] [
    fhir:code [ fhir:v "013" ] ;
    fhir:display [ fhir:v "AML with BCR-ABL1" ]
      ] [
    fhir:code [ fhir:v "021" ] ;
    fhir:display [ fhir:v "B lymphoblastic leukemia/lymphoma with BCR-ABL1" ]
      ] [
    fhir:code [ fhir:v "022" ] ;
    fhir:display [ fhir:v "B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged" ]
      ] [
    fhir:code [ fhir:v "023" ] ;
    fhir:display [ fhir:v "B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1)" ]
      ] [
    fhir:code [ fhir:v "024" ] ;
    fhir:display [ fhir:v "B-lymphoblastic leukemia/lymphoma with IGH/IL3" ]
      ] [
    fhir:code [ fhir:v "025" ] ;
    fhir:display [ fhir:v "B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1)" ]
      ] [
    fhir:code [ fhir:v "041" ] ;
    fhir:display [ fhir:v "Mixed phenotype acute leukemia with BCR-ABL1" ]
      ] [
    fhir:code [ fhir:v "042" ] ;
    fhir:display [ fhir:v "Mixed-phenotype acute leukemia with KMT2A-rearranged" ]
      ] [
    fhir:code [ fhir:v "051" ] ;
    fhir:display [ fhir:v "Chronic myelogenous leukemia BCR-ABL1 positive" ]
      ] [
    fhir:code [ fhir:v "052" ] ;
    fhir:display [ fhir:v "JAK2 V617F mutation" ]
      ] [
    fhir:code [ fhir:v "053" ] ;
    fhir:display [ fhir:v "Myeloid and lymphoid neoplasms with PDGFRA rearrangement" ]
      ] [
    fhir:code [ fhir:v "054" ] ;
    fhir:display [ fhir:v "Myeloid and lymphoid neoplasms with PDGFRB rearrangement" ]
      ] [
    fhir:code [ fhir:v "055" ] ;
    fhir:display [ fhir:v "Myeloid and lymphoid neoplasms with FGFR1 rearrangement" ]
      ] [
    fhir:code [ fhir:v "090" ] ;
    fhir:display [ fhir:v "(1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常" ]
      ] [
    fhir:code [ fhir:v "091" ] ;
    fhir:display [ fhir:v "同時有兩種(含)以上上述之分子檢驗異常" ]
      ] [
    fhir:code [ fhir:v "092" ] ;
    fhir:display [ fhir:v "同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常" ]
      ] [
    fhir:code [ fhir:v "8XX" ] ;
    fhir:display [ fhir:v "Molecular study after chemotherapy or immunotherapy or target therapy" ]
      ] [
    fhir:code [ fhir:v "988" ] ;
    fhir:display [ fhir:v "不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4)" ]
      ] [
    fhir:code [ fhir:v "998" ] ;
    fhir:display [ fhir:v "有執行分子生物學檢查，但結果無法判斷" ]
      ] [
    fhir:code [ fhir:v "999" ] ;
    fhir:display [ fhir:v "(1) 病歷未記載或不詳 (2) 未執行分子生物學檢查" ]
      ] ) . #